Lookout for These Two Stocks: Agios Pharmaceuticals, Inc. (AGIO), CarMax Inc. (KMX)

Leslie Hanson
January 13, 2018

Manning & Napier Advisors Llc bought 393,318 shares as the company's stock declined 14.80% while stock markets rallied.

In taking a look at technical levels, shares are trading 2.56% away from the 50 day simple moving average and 13.41% away from the 200 day simple moving average. Sell-side analyst recommendations point to a short term price target of $3 on the company shares. Agios Pharmaceuticals Inc has a 1-year low of $39.24 and a 1-year high of $72.73. 505,000 shares of the company traded hands, compared to its average volume of 474,250. (NASDAQ:AGIO) advice adding it to buy candidate list. It has underperformed by 8.18% the S&P500. Over the last ninety days, insiders sold 29,130 shares of company stock valued at $1,844,260. (AGIO). The consensus rating is 1.8, indicating analysts in general look favorably on the company's future prospects.

Examining Institutional Ownership at Agios Pharmaceuticals, Inc.

The stock decreased 1.26% or $0.3 during the last trading session, reaching $23.45. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since January 10, 2017 and is uptrending. It has outperformed by 3.21% the S&P500.

Since August 1, 2017, it had 0 buys, and 14 sales for $14.88 million activity. 15,000 shares valued at $975,000 were sold by Biller Scott on Monday, September 11. Agios Pharmaceuticals, Inc. (AGIO) is now moving with upbeat trend. (NASDAQ:AGIO) shares. Schenkein David P also sold $5.61 million worth of Agios Pharmaceuticals, Inc.

As regular trading ended, Pluristem Therapeutics Inc. Public Employees Retirement System of OH now owns 18,353 shares of the biopharmaceutical company's stock valued at $944,000 after acquiring an additional 6,338 shares in the last quarter. AGIO's SI was 6.32M shares in January as released by FINRA. (NASDAQ:AGIO) to report earnings on February, 15. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping the Zacks' consensus estimate of ($1.78) by $0.19. Of those analysts, 5 rate stock as a Strong Buy, 0 rate it as Hold, and just no analyst rates it as a Moderate Sell. Therefore 75% are positive.

Other equities research analysts have also recently issued reports about the company. The business's quarterly revenue was up 26.4% on a year-over-year basis. As per Monday, December 7, the company rating was downgraded by Leerink Swann. As per Monday, June 19, the company rating was maintained by Keefe Bruyette & Woods. The stock of Agios Pharmaceuticals, Inc. (NYSE:TRV) earned "Buy" rating by RBC Capital Markets on Thursday, July 20. Deerfield reported 0.63% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, November 9 with "Neutral" rating. Northland Capital has "Outperform" rating and $132 target.

Investors sentiment decreased to 1.21 in 2017 Q3. Its down 0.23, from 1.24 in 2017Q2. Deerfield Mngmt Commerce reported 208,000 shares. The New York-based Morgan Stanley has invested 0% in the stock. Retail Bank Of Mellon has 0% invested in Agios Pharmaceuticals, Inc. Finally, BidaskClub lowered shares of Agios Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday, December 16th. 17,182 are owned by Profund Advsrs Ltd Liability. Oppenheimer maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Arrowmark Colorado Lc stated it has 138,368 shares. 966,152 are held by Balyasny Asset Mgmt Limited. Perigon Wealth Management Llc, a California-based fund reported 33 shares. Ameriprise Finance holds 0% or 57,504 shares.

Meanwhile, during the same quarter Agios Pharmaceuticals, Inc. Travelers had 48 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was maintained by BTIG Research with "Buy" on Wednesday, October 4. The firm has a market capitalization of $3,270.00, a P/E ratio of -10.74 and a beta of 1.83. Cantley sold 4,000 shares of the business's stock in a transaction that occurred on Tuesday, October 17th. The firm has "Positive" rating given on Wednesday, March 30 by Susquehanna. (NYSE:TRV) to report earnings on January, 23 before the open. Wedbush has "Hold" rating and $60.0 target. The company was maintained on Wednesday, October 26 by Deutsche Bank. The stock has "Hold" rating by KeyBanc Capital Markets on Tuesday, August 22. The rating was initiated by Barclays Capital with "Overweight" on Friday, January 6. Its down 1.54% from 6.42 million shares, reported previously. S&CO Inc. purchased a new stake in Agios Pharmaceuticals during the third quarter worth approximately $227,000. Verizon Communications Inc (NYSE:VZ) was raised too. Insiders own 5.43% of the company's stock. Utah Retirement has 0.04% invested in Lennar Corporation (NYSE:LEN) for 36,543 shares. Northern Tru Corp holds 228,626 shares. Cambridge Investment Research Advsrs Inc accumulated 325,246 shares. 368,870 are held by Rhumbline Advisers. Axa accumulated 161,743 shares or 0.05% of the stock. Invesco Ltd reported 985,932 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article